PMVP

0.876033.13%
LD

Laurie D. Stelzer

Independent Director

Ms. Laurie D. Stelzer, M.B.A., is Independent Chairperson of PMV Pharmaceuticals, Inc. from June 4, 2026. She is Independent Director of MBX Biosciences, Inc. from January 20, 2026. She was Chief Financial Officer of Kailera Therapeutics, Inc until November 2025. She is an Independent Director of Sionna Therapeutics, Inc. since November 12, 2024. She serves as Independent Director of Spyre Therapeutics, Inc. since November 28, 2023. Ms. Stelzer has served as the Chief Financial Officer of Kailera Therapeutics, Inc. (“Kailera”) since January 2025. Prior to Kailera, Ms. Stelzer served as the Chief Financial Officer of Orna Therapeutics (“Orna”) from May 2024 to January 2025. She was Chief Financial Officer of ReNAgade Therapeutics Management Inc. from September 2023. She had been an Independent Director of Surface Oncology, Inc. since February 22, 2018 until September 8, 2023. She was Chief Financial Officer of Mirati Therapeutics, Inc. from May 16, 2022 until September 08, 2023 and joined Mirati in 2022. She remained with Mirati Therapeutics, Inc. through October 2023. She had been Executive Vice President and Chief Financial Officer at Arena Pharmaceuticals, Inc since March 16, 2020. She was Director at Longboard Pharmaceuticals, Inc. since October 2020. She serves as Independent Director at PMV Pharmaceuticals, Inc. since August 2020. Ms. Stelzer served as Chief Financial Officer and Senior Vice President of Halozyme Therapeutics, Inc. from June 15, 2015 to March 2, 2020 and served as Principal Financial and Accounting Officer. She served as the Senior Vice President of Finance supporting R&D, Technical Operations and M&A at Shire, Inc since April 2014 until January 2015. Prior to that, she was the Division Chief Financial Officer for the Regenerative Medicine Division and the Head of Investor Relations at Shire from March 2012 to April 2014. She held positions of increasing responsibility at Amgen, Inc., including Interim Treasurer, Head of Emerging Markets Expansion, Executive Director of Global Commercial Finance and Head of Global Accounting. She holds experience of working in pharmaceutical industry. Prior to joining she held senior management roles at Shire Plc (acquired by Takeda), including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division and Head of Investor Relations. Previously, she held positions of increasing responsibility during her career at Amgen, Inc., spanning the areas of finance, treasury, global accounting and international/emerging markets. Before Shire, she worked at Amgen Incorporated, serving in positions of increasing responsibility in the areas of Finance, Treasury, Global Accounting and International/Emerging Markets. Ms. Stelzer earned her B.S. in Accounting from Arizona State University and an MBA from University of California, Los Angeles, Anderson School of Management.

Positions